• Molecular NameTyloxapol
  • SynonymMacrocyclon
  • Weight364.401
  • Drugbank_IDDB06439
  • ACS_NO25301-02-4
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.71
  • pkaN/A
  • LogD (pH=7, predicted)2.71
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.34
  • LogSw (predicted, AB/LogsW2.0)0.03
  • Sw (mg/ml) (predicted, ACD/Labs)0.17
  • No.of HBond Donors1
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds7
  • TPSA71.78
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions, administered by inhalation through a nebulizer or with a stream of oxygen. With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAcute oral LD50 in 1000 mg/kg in mouse and 5000 mg/kg in rat.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A